Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• AoyagiKKouhujiKKizakiJIsobeTHashimotoKShirouzuKMolecular targeting to treat gastric cancerWorld J Gastroenterol20142038137411375525320512
   PubMedGoogle Scholar
• SalimansMMvan BusselMJBrownCSSpaanWJRecombinant parvovirus B19 capsids as a new substrate for detection of B19-specific IgG and IgM antibodies by an enzyme-linked immunosorbent assayJ Virol Methods19923932472581430069
   PubMedGoogle Scholar
• CunninghamDJostLMPurkalneGOliveiraJForceEGTESMO minimum clinical recommendations for diagnosis, treatment and follow-up of gastric cancerAnn Oncol200516Suppl 1i22i2315888740
   PubMedGoogle Scholar
• SasakoMSakuramotoSKataiHFive-year outcomes of a randomized Phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancerJ Clin Oncol201129334387439322010012
   PubMed Web of Science ®Google Scholar
• AjaniJAEvolving chemotherapy for advanced gastric cancerOncologist200510Suppl 3495816368871
   PubMed Web of Science ®Google Scholar
• GlimeliusBHoffmanKHaglundUNyrénOSjödénPOInitial or delayed chemotherapy with best supportive care in advanced gastric cancerAnn Oncol1994521891908186165
   PubMedGoogle Scholar
• PyrhönenSKuitunenTNyandotoPKouriMRandomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBr J Cancer19957135875917533517
   PubMed Web of Science ®Google Scholar
• FordHEMarshallABridgewaterJADocetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, Phase 3 randomised controlled trialLancet Oncol2014151788624332238
   PubMed Web of Science ®Google Scholar
• WongHYauTTargeted therapy in the management of advanced gastric cancer: are we making progress in the era of personalized medicine?Oncologist201217334635822334453
   PubMed Web of Science ®Google Scholar
• QiWXShenZTangLNYaoYThe role of anti-VEGF agents in the treatment of advanced gastric cancer: a meta-analysis of randomized controlled trialsTumour Biol20143587675768324801910
   PubMedGoogle Scholar
• CilibertoDStaropoliNCagliotiFA systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: evidence does not translate?Cancer Biol Ther20151681148115926061272
   PubMed Web of Science ®Google Scholar
• Abdel-RahmanOTargeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspectsCrit Rev Oncol Hematol2015931182724970311
   PubMed Web of Science ®Google Scholar
• BangYJAdvances in the management of HER2-positive advanced gastric and gastroesophageal junction cancerJ Clin Gastroenterol201246863764822751336
   PubMed Web of Science ®Google Scholar
• CarratoASwieboda-SadlejAStaszewska-SkurczynskaMFluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, Phase III trialJ Clin Oncol201331101341134723358972
   PubMed Web of Science ®Google Scholar
• MoherDPhamBJonesADoes quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?Lancet199835291286096139746022
   PubMed Web of Science ®Google Scholar
• ZintzarasEIoannidisJPHeterogeneity testing in meta-analysis of genome searchesGenet Epidemiol200528212313715593093
   PubMed Web of Science ®Google Scholar
• YusufSPetoRLewisJCollinsRSleightPBeta blockade during and after myocardial infarction: an overview of the randomized trialsProg Cardiovasc Dis19852753353712858114
   PubMed Web of Science ®Google Scholar
• FuruseKKawaharaMHasegawaKEarly Phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancerInt J Clin Oncol20016523624111723745
   PubMedGoogle Scholar
• WilkeHMuroKVan CutsemERamucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised Phase III trialLancet Oncol201415111224123525240821
   PubMed Web of Science ®Google Scholar
• ShenLLiJXuJBevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, Phase III study (AVATAR study)Gastric cancer201518116817624557418
   PubMed Web of Science ®Google Scholar
• SatohTXuRHChungHCLapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN – a randomized, Phase III studyJ Clin Oncol201432192039204924868024
   PubMed Web of Science ®Google Scholar
• FuchsCSTomasekJYongCJRamucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, Phase III trialLancet20143839911313924094768
   PubMed Web of Science ®Google Scholar
• WaddellTChauICunninghamDEpirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label Phase III trialLancet Oncol201314648148923594787
   PubMed Web of Science ®Google Scholar
• OhtsuAAjaniJABaiYXEverolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, Phase III GRANITE-1 studyJ Clin Oncol201331313935394324043745
   PubMed Web of Science ®Google Scholar
• LordickFKangYKChungHCCapecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label Phase III trialLancet Oncol201314649049923594786
   PubMed Web of Science ®Google Scholar
• OhtsuAShahMAVan CutsemEBevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled Phase III studyJ Clin Oncol201129303968397621844504
   PubMed Web of Science ®Google Scholar
• BangYJVan CutsemEFeyereislovaATrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase III, open-label, randomised controlled trialLancet2010376974268769720728210
   PubMed Web of Science ®Google Scholar
• ZhangYWuSNovel therapy for advanced gastric cancerWorld J Gastrointest Oncol201571126327026600926
   PubMed Web of Science ®Google Scholar
• RanpuraVHapaniSWuSTreatment-related mortality with bevacizumab in cancer patients: a meta-analysisJAMA2011305548749421285426
   PubMed Web of Science ®Google Scholar
• SivendranSLiuZPortasLJJrTreatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: a meta-analysisCancer Treat Rev201238791992522651902
   PubMed Web of Science ®Google Scholar
• SchutzFAJeYRichardsCJChoueiriTKMeta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitorsJ Clin Oncol201230887187722312105
   PubMed Web of Science ®Google Scholar
• ZhangDYeJXuTXiongBTreatment related severe and fatal adverse events with cetuximab in colorectal cancer patients: a meta-analysisJ Chemother201325317017523783142
   PubMed Web of Science ®Google Scholar
• QiWXHuangYJYaoYShenZMinDLIncidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysisPLoS One201386e6516623785409
   PubMedGoogle Scholar
• ChoueiriTKJeYSonpavdeGIncidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitorsAnn Oncol20132482092209723658373
   PubMed Web of Science ®Google Scholar
• QiWXFuSZhangQGuoXMBevacizumab increases the risk of infections in cancer patients: a systematic review and pooled analysis of 41 randomized controlled trialsCrit Rev Oncol Hematol201594332333625749417
   PubMed Web of Science ®Google Scholar
• QiWXFuSZhangQGuoXMIncidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysisBMC Med20141220325369798
   PubMed Web of Science ®Google Scholar